Characterization of an Iodinated Rectal Spacer for Prostate Photon and Proton Radiation Therapy

被引:10
作者
Kamran, Sophia C. [1 ]
McClatchy, David M. [1 ]
Pursley, Jennifer [1 ]
V. Trofimov, Alexei [1 ]
Remillard, Kyla [1 ]
Saraf, Anurag [1 ,2 ]
Ghosh, Anushka [1 ]
Thabet, Ashraf [3 ]
Sutphin, Patrick [3 ]
Miyamoto, David T. [1 ]
Efstathiou, Jason A. [1 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Harvard Radiat Oncol Program, Boston, MA 02115 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Intervent Radiol, Boston, MA 02115 USA
关键词
DOSE-RATE BRACHYTHERAPY; HYDROGEL; RADIOTHERAPY; OUTCOMES; TRIAL; RISK;
D O I
10.1016/j.prro.2021.09.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Conventional rectal spacers (nonI-SPs) are low-contrast on computed tomography (CT), often necessitating magnetic resonance imaging for accurate delineation. A new formulation of spacers (I-SPs) incorporates iodine to improve radiopacity and CT visualization. We characterized placement, stability, and plan quality of I-SPs compared to nonI-SPs. Methods and Materials: Patients with intact prostate cancer (n = 50) treated with I-SPs and photons were compared to randomly selected patients (n = 50) with nonI-SPs (photon or proton therapy). The I-SP was contoured on the planning CT and cone beam CTs at 3 timepoints: first, middle, and final treatment (n = 200 scans). I-SPs Hounsfield units (HU), volume, surface area (SA), centroid position relative to prostate centroid, and distance between prostate/rectum centroids were compared on the planning CTs between each cohort. I-SP changes were evaluated on cone beam CTs over courses of treatment. Dosimetric evaluations of plan quality and robustness were performed. I-SP was tested in a phantom to characterize its relative linear stopping power for protons. Results: I-SPs yielded a distinct visible contrast on planning CTs compared to nonI-SPs (HU 138 vs 12, P < .001), allowing delineation on CT alone. The delineated volume and SA of I-SPs were smaller than nonI-SPs (volume 8.9 vs 10.6mL, P < .001; SA28 vs 35 cm(2), P < .001), yet relative spacer position and prostate-rectal separation were similar (P = .79). No significant change in HU, volume, SA, or relative position of the ISPs hydrogel occurred over courses of treatment (all P > .1). Dosimetric analysis concluded there were no significant changes in plan quality or robustness for I-SPs compared to nonI-SPs. The I-SP relative linear stopping power was 1.018, necessitating HU override for proton planning. Conclusions: I-SPs provide a manifest CT contrast, allowing for delineation on planning CT alone with no magnetic resonance imaging necessary. I-SPs radiopacity, size, and relative position remained stable over courses of treatment from 28 to 44 fractions. No changes in plan quality or robustness were seen comparing I-SPs and nonI-SPs. (C) 2021 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:135 / 144
页数:10
相关论文
共 19 条
[1]   Addition of Iodinated Contrast to Rectal Hydrogel Spacer to Facilitate MRI-Independent Target Delineation and Treatment Planning for Prostate Cancer [J].
Atluri, Pramukh S. ;
Gannavarapu, Bhavani S. ;
Timmerman, Robert D. ;
Garant, Aurelie ;
Hannan, Raquibul ;
Folkert, Michael R. ;
Desai, Neil B. .
PRACTICAL RADIATION ONCOLOGY, 2019, 9 (06) :E528-E533
[2]   Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial [J].
Brand, Douglas H. ;
Tree, Alison C. ;
Ostler, Peter ;
van der Voet, Hans ;
Loblaw, Andrew ;
Chu, William ;
Ford, Daniel ;
Tolan, Shaun ;
Jain, Suneil ;
Martin, Alexander ;
Staffurth, John ;
Camilleri, Philip ;
Kancherla, Kiran ;
Frew, John ;
Chan, Andrew ;
Dayes, Ian S. ;
Henderson, Daniel ;
Brown, Stephanie ;
Cruickshank, Clare ;
Burnett, Stephanie ;
Duffton, Aileen ;
Griffin, Clare ;
Hinder, Victoria ;
Morrison, Kirsty ;
Naismith, Olivia ;
Hall, Emma ;
van As, Nicholas .
LANCET ONCOLOGY, 2019, 20 (11) :1531-1543
[3]   Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer [J].
Catton, Charles N. ;
Lukka, Himu ;
Gu, Chu-Shu ;
Martin, Jarad M. ;
Supiot, Stephane ;
Chung, Peter W. M. ;
Bauman, Glenn S. ;
Bahary, Jean-Paul ;
Ahmed, Shahida ;
Cheung, Patrick ;
Tai, Keen Hun ;
Wu, Jackson S. ;
Parliament, Matthew B. ;
Tsakiridis, Theodoros ;
Corbett, Tom B. ;
Tang, Colin ;
Dayes, Ian S. ;
Warde, Padraig ;
Craig, Tim K. ;
Julian, Jim A. ;
Levine, Mark N. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (17) :1884-+
[4]   Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal-Prostate Interface and Spare the Rectum: A Case Report [J].
Conroy, Dylan ;
Becht, Kelly ;
Forsthoefel, Matthew ;
Pepin, Abigail N. ;
Lei, Siyuan ;
Rashid, Abdul ;
Collins, Brian Timothy ;
Lischalk, Jonathan W. ;
Suy, Simeng ;
Aghdam, Nima ;
Hankins, Ryan Andrew ;
Collins, Sean P. .
FRONTIERS IN ONCOLOGY, 2021, 10
[5]   Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial [J].
Dearnaley, David ;
Syndikus, Isabel ;
Mossop, Helen ;
Khoo, Vincent ;
Birtle, Alison ;
Bloomfield, David ;
Graham, John ;
Kirkbride, Peter ;
Logue, John ;
Malik, Zafar ;
Money-Kyrle, Julian ;
O'Sullivan, Joe M. ;
Panades, Miguel ;
Parker, Chris ;
Patterson, Helen ;
Scrase, Christopher ;
Staffurth, John ;
Stockdale, Andrew ;
Tremlett, Jean ;
Bidmead, Margaret ;
Mayles, Helen ;
Naismith, Olivia ;
South, Chris ;
Gao, Annie ;
Cruickshank, Clare ;
Hassan, Shama ;
Pugh, Julia ;
Griffin, Clare ;
Hall, Emma .
LANCET ONCOLOGY, 2016, 17 (08) :1047-1060
[6]   Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer [J].
Donovan, J. L. ;
Hamdy, F. C. ;
Lane, J. A. ;
Mason, M. ;
Metcalfe, C. ;
Walsh, E. ;
Blazeby, J. M. ;
Peters, T. J. ;
Holding, P. ;
Bonnington, S. ;
Lennon, T. ;
Bradshaw, L. ;
Cooper, D. ;
Herbert, P. ;
Howson, J. ;
Jones, A. ;
Lyons, N. ;
Salter, E. ;
Thompson, P. ;
Tidball, S. ;
Blaikie, J. ;
Gray, C. ;
Bollina, P. ;
Catto, J. ;
Doble, A. ;
Doherty, A. ;
Gillatt, D. ;
Kockelbergh, R. ;
Kynaston, H. ;
Paul, A. ;
Powell, P. ;
Prescott, S. ;
Rosario, D. J. ;
Rowe, E. ;
Davis, M. ;
Turner, E. L. ;
Martin, R. M. ;
Neal, D. E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (15) :1425-1437
[7]   A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer [J].
Folkert, Michael R. ;
Zelefsky, Michael J. ;
Hannan, Raquibul ;
Desai, Neil B. ;
Lotan, Yair ;
Laine, Aaron M. ;
Kim, D. W. . Nathan ;
Neufeld, Sarah Hardee ;
Hornberger, Brad ;
Kollmeier, Marisa A. ;
McBride, Sean ;
Ahn, Chul ;
Roehrborn, Claus ;
Timmerman, Robert D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (01) :101-109
[8]  
Hall WA, 2021, LANCET ONCOL, V22, P11, DOI 10.1016/S1470-2045(20)30639-2
[9]   10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer [J].
Hamdy, F. C. ;
Donovan, J. L. ;
Lane, J. A. ;
Mason, M. ;
Metcalfe, C. ;
Holding, P. ;
Davis, M. ;
Peters, T. J. ;
Turner, E. L. ;
Martin, R. M. ;
Oxley, J. ;
Robinson, M. ;
Staffurth, J. ;
Walsh, E. ;
Bollina, P. ;
Catto, J. ;
Doble, A. ;
Doherty, A. ;
Gillatt, D. ;
Kockelbergh, R. ;
Kynaston, H. ;
Paul, A. ;
Powell, P. ;
Prescott, S. ;
Rosario, D. J. ;
Rowe, E. ;
Neal, D. E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (15) :1415-1424
[10]   Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer [J].
Hoffman, Karen E. ;
Voong, K. Ranh ;
Levy, Lawrence B. ;
Allen, Pamela K. ;
Choi, Seungtaek ;
Schlembach, Pamela J. ;
Lee, Andrew K. ;
McGuire, Sean E. ;
Quynh Nguyen ;
Pugh, Thomas J. ;
Frank, Steven J. ;
Kudchadker, Rajat J. ;
Du, Weiliang ;
Kuban, Deborah A. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (29) :2943-+